ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
A Treatment IND for Retrovir Brand Zidovudine (AZT) Therapy of Pediatric Patients With HIV Disease

This study is ongoing, but not recruiting participants.

Sponsors and Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Glaxo Wellcome
Information provided by: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT00000662
  Purpose

To facilitate the use of zidovudine (AZT) in children who are 3 months to 12 years of age who are HIV-infected and either symptomatic or have a CD4 cell count < 400 cells/mm3 and to monitor adverse effects of AZT.

Previous studies with pediatric patients have shown improvements in clinical, immunologic, and virologic parameters with administration of AZT.


Condition Intervention
HIV Infections
Drug: Zidovudine

MedlinePlus related topics:   AIDS   

Drug Information available for:   Zidovudine   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment
Official Title:   A Treatment IND for Retrovir Brand Zidovudine (AZT) Therapy of Pediatric Patients With HIV Disease

Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Detailed Description:

Previous studies with pediatric patients have shown improvements in clinical, immunologic, and virologic parameters with administration of AZT.

This Treatment IND (investigational new drug) is an open label, uncontrolled protocol. AZT is ordered and prescribed by the patient's physician. The physician is responsible for obtaining informed consent, assuring that the patient meets the eligibility criteria, dispensing the medication to the patient, monitoring the patient's condition on treatment, and reporting required data to the project coordinating center.

  Eligibility
Ages Eligible for Study:   3 Months to 12 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria

Concurrent Treatment:

Allowed:

  • Blood transfusions for hematologic toxicity.

Criteria for children 3 months to less than 15 months of age:

  • Patient must be HIV antibody-positive by repeated reactive screening test (e.g., ELISA) and positive confirmatory test (e.g., Western blot).

OR

  • If antibody-negative, patient must have two positive p24 antigen determinations performed at least one week apart or have had a positive HIV culture.

Patients must meet two of the following criteria:

  • Be HIV culture positive or p24 antigen positive.
  • Have at least one of the Class P-2 symptoms (by CDC criteria).

Be immunosuppressed defined as having:

  • CD4+(T4) lymphocytes = or < 400 cells/mm3.
  • Abnormal age adjusted immunoglobulin levels (IgG or IgA). Decreased helper/suppressor ratio < 1.0.

Note:

  • In general, abnormal values for any of the above lab tests should be confirmed in 2 measurements at least 1 week apart, and other clinical causes for these abnormalities should be ruled out.

Criteria for children 15 months to 12 years of age:

  • Patient must be HIV antibody-positive by repeated reactive screening test (e.g., ELISA) and positive confirmatory test (e.g., Western blot).

OR

  • If antibody-negative, patient must have two positive p24 antigen determinations performed at least one week apart or have had a positive HIV culture.

Patients must meet one of the following criteria:

  • Have at least one of the class P-2 symptoms (by CDC criteria).
  • Be immunosuppressed defined as having CD4+(T4) lymphocytes = or < 400 cells/mm3, based on two measurements at least 1 week apart.

Exclusion Criteria

Co-existing Condition:

Patients with known hypersensitivity to AZT are excluded.

Patients with the following are excluded:

  • Failure to meet inclusion criteria.
  • Inability to obtain signed informed consent from a parent or legal guardian.
  • Enrollment in another treatment protocol that expressly prohibits concomitant treatment with zidovudine (AZT).
  • Enrollment in another clinical trial in which AZT is a treatment.
  • Known hypersensitivity to AZT.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000662

Locations
United States, North Carolina
Glaxo Wellcome Inc    
      Research Triangle Park, North Carolina, United States, 27709

Sponsors and Collaborators
  More Information


Click here for more information about Zidovudine  This link exits the ClinicalTrials.gov site
 

Study ID Numbers:   TX 304, FDA 43A
First Received:   November 2, 1999
Last Updated:   August 1, 2008
ClinicalTrials.gov Identifier:   NCT00000662
Health Authority:   United States: Federal Government

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Drugs, Investigational  
Acquired Immunodeficiency Syndrome  
AIDS-Related Complex  
Zidovudine  

Study placed in the following topic categories:
Virus Diseases
Sexually Transmitted Diseases, Viral
HIV Infections
Sexually Transmitted Diseases
Acquired Immunodeficiency Syndrome
Zidovudine
AIDS-Related Complex
Retroviridae Infections
Immunologic Deficiency Syndromes

Additional relevant MeSH terms:
Antimetabolites
Anti-Infective Agents
RNA Virus Infections
Anti-HIV Agents
Slow Virus Diseases
Immune System Diseases
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Infection
Antiviral Agents
Pharmacologic Actions
Reverse Transcriptase Inhibitors
Anti-Retroviral Agents
Therapeutic Uses
Lentivirus Infections
Nucleic Acid Synthesis Inhibitors

ClinicalTrials.gov processed this record on December 03, 2008




Links to all studies - primarily for crawlers